These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28675307)

  • 1. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
    Macaluso M; Oliver H; Sohail Z
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.
    Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I
    J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone.
    Schoretsanitis G; Spina E; Hiemke C; de Leon J
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):625-639. PubMed ID: 29776316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone for the treatment of schizoaffective disorder.
    Alphs L; Fu DJ; Turkoz I
    Expert Opin Pharmacother; 2016; 17(6):871-83. PubMed ID: 26934062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone.
    Schoretsanitis G; Spina E; Hiemke C; de Leon J
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1237-1253. PubMed ID: 30449206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preclinical discovery and development of paliperidone for the treatment of schizophrenia.
    Wesołowska A; Jastrzębska-Więsek M; Cios A; Partyka A
    Expert Opin Drug Discov; 2020 Mar; 15(3):279-292. PubMed ID: 31661992
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period.
    Zamora Rodríguez FJ; Benítez Vega C; Sánchez-Waisen Hernández MR; Guisado Macías JA; Vaz Leal FJ
    Pharmacopsychiatry; 2017 Jan; 50(1):38-40. PubMed ID: 27414740
    [No Abstract]   [Full Text] [Related]  

  • 13. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report.
    Matsuura H; Kimoto S; Harada I; Naemura S; Yamamuro K; Kishimoto T
    BMC Psychiatry; 2016 May; 16():161. PubMed ID: 27229149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state.
    Kerbusch-Herben V; Cleton A; Berwaerts J; Vandebosch A; Remmerie B
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):371-7. PubMed ID: 27129010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].
    Bellantuono C; Santone G
    Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
    Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
    Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J
    Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.